Quick Takeaways
- Boxer Capital, LLC has 6 issuer positions tracked on this page.
- Estimated disclosed ownership value: $293,244,500.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Boxer Capital, LLC
- Location
- San Diego, CA
- Summary
- The estimated value of insider holdings of Boxer Capital, LLC is at least $293,244,500 dollars as of 14 May 2024. Boxer Capital, LLC is the Other* of Tango Therapeutics, Inc. and owns shares of Tango Therapeutics, Inc. (TNGX) stock worth about $139.49M. Boxer Capital, LLC is the Other* of Tyra Biosciences, Inc. and owns shares of Tyra Biosciences, Inc. (TYRA) stock worth about $94.19M. Boxer Capital, LLC is the Other* of iTeos Therapeutics, Inc. and owns shares of iTeos Therapeutics, Inc. stock worth about $51.57M. Boxer Capital, LLC is the 10%+ Owner of Odonate Therapeutics, Inc. and owns shares of Odonate Therapeutics, Inc. stock worth about $6.6M. Boxer Capital, LLC is the Aaron Davis, the CEO of Boxer Capital, LLC, is a director of Rain Oncology Inc. of Rain Oncology Inc. and owns shares of Rain Oncology Inc. stock worth about $1.39M.
- Signature
- /s/ Aaron I. Davis, Chief Executive Officer, Boxer Capital, LLC
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Boxer Capital, LLC and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
What Changed
- Largest disclosed position: Tango Therapeutics, Inc. ($139,494,711).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Boxer Capital, LLC
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| TNGX | Tango Therapeutics, Inc. | Other* | $139,494,711 | 13 Oct 2023 | ||
| TYRA | Tyra Biosciences, Inc. | Other* | $94,186,205 | 06 Feb 2024 | ||
| ITOS | iTeos Therapeutics, Inc. | Other* | $51,571,013 | 10 May 2024 | ||
| ODT | Odonate Therapeutics, Inc. | 10%+ Owner | $6,598,394 | 22 Nov 2021 | ||
| RAIN | Rain Oncology Inc. | Aaron Davis, the CEO of Boxer Capital, LLC, is a director of Rain Oncology Inc. | $1,394,177 | 22 May 2023 | ||
| MRTX | Mirati Therapeutics, Inc. | Other* | 23 Jan 2024 |
Insider Transactions Reported by Boxer Capital, LLC:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.